Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 1/20 | 0.37 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.37 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.37 |
| ▸ | TLR2 | O60603 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 8/20 | 0.36 |
| ▸ | MMP2 | P08253 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2952566 | 0.99 | TLR2 (0.36) | GABBR2GABRR1GABBR1TLR2ACHE | |
| SCHEMBL1892403 | 0.88 | TLR2 (0.35) | TLR2ACHEMMP2EPHX1LMNA | |
| SCHEMBL2948790 | 0.85 | ACHE (0.41) | GABBR2GABRR1GABBR1ACHEMMP2 | |
| SCHEMBL2954561 | 0.84 | LMNA (0.33) | GABBR2GABRR1GABBR1LMNALPAR1 | |
| SCHEMBL2951050 | 0.83 | GABBR2 (0.36) | GABBR2GABRR1GABBR1ACHEMMP2 | |
| SCHEMBL2948184 | 0.83 | CTSK (0.35) | — | |
| SCHEMBL2948239 | 0.81 | GABBR2 (0.35) | GABBR2GABRR1GABBR1LMNALPAR1 | |
| SCHEMBL2954529 | 0.80 | GABBR2 (0.34) | GABBR2GABRR1GABBR1LMNALPAR1 | |
| SCHEMBL2947858 | 0.80 | ACHE (0.46) | GABBR2GABRR1GABBR1ACHEMMP2 | |
| SCHEMBL1888061 | 0.79 | LPAR2 (0.40) | ACHEMMP2EPHX1LMNAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7749985-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2010-07-06 | — | — | US | claimed |
| US-20090286759-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2009-11-19 | — | — | US | claimed |
| US-7749985-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20090286759-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-7585996-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-20080146526-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286759-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | APEH, NAPEPLD, AASDHPPT | GABBR2 804/4885GABRR1 1069/4885GABBR1 598/4885 |
| US-20080146526-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | APEH, NAPEPLD, AASDHPPT | GABBR2 804/4885GABRR1 1069/4885GABBR1 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.